Abstract
According to WHO, cancer is the second leading cause of death in the world and the seventh cause of death in Indonesia. Currently, cancer sufferers are increasing every year and become a national problem in health. Terbium-161 (161Tb) is a low β−-emitter of radiolanthanide (Eβ - an average of 0.150 MeV and t1/2 for 6.9 days) that is potential for cancer therapy as an alternative to 177Lu which has been widely used in nuclear medicine. Physico-chemical characterization of 161Tb radioisotope in the form of 161TbCl3 final product solution has been studied including radiochemical purity, radionuclide purity, clarity, acidity (pH), and its stability. Irradiation of the Gd2O3 enriched target (98.4% 160Gd isotope enrichment) was carried out at Bandung TRIGA 2000 reactor for ± 3 days. The separation of 161Tb radionuclide from the Gd/Tb matrix has been done by the extraction chromatography method using two pieces of LN (Eichrom) resin cartridge column. The radiochemical purity of the final product of 161TbCl3 radioisotope solution was determined using paper chromatography and paper electrophoresis methods. Radionuclide purity of fractions resulted from separation as well as the final products of radioisotope 161TbCl3 was determined through analysis using a γ-ray spectrometer equipped with a multichannel analyzer (MCA) and HP-Ge detector. The clarity of the solution was determined visually, while the determination of acidity (pH) was carried out using the universal pH indicator paper. In this study, the final product of 161TbCl3 solution has Physico-chemical characteristics that meet the requirements for nuclear medicine application, namely clear, has a pH of ∼ 1, radiochemical purity of 99.31 ± 0.62%, and radionuclide purity of 99.96 ± 0.03%. The stability of radionuclide purity still meets the requirements (> 99%) for 2 weeks after preparing the final product, but 161TbCl3 solution with radiochemical purity more than 95% was stable until 3 weeks at room temperature.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
